{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:32:44Z","timestamp":1787016764046,"version":"build-2736575974"},"reference-count":84,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    With 2 to 3% of the worldwide population chronically infected, hepatitis C virus (HCV) infection continues to be a major health care burden. Unfortunately, current interferon-based treatment options are not effective in all patients and are associated with significant side effects. Consequently, there is an ongoing need to identify and develop new anti-HCV therapies. Toward this goal, we previously developed a cell-based HCV infection assay for antiviral compound screening based on a low-multiplicity-of-infection approach that uniquely allows for the identification of antiviral compounds that target cell culture-derived HCV (HCVcc) at any step of the viral infection cycle. Using this assay, here we report the screening of the NCI Diversity Set II library, containing 1,974 synthesized chemical compounds, and the identification of compounds with specific anti-HCV activity. In combination with toxicity counterscreening, we identified 30 hits from the compound library, 13 of which showed reproducible and dose-dependent inhibition of HCV with mean therapeutic indices (50% cytotoxic concentration [CC\n                    <jats:sub>50<\/jats:sub>\n                    ]\/50% effective concentration [EC\n                    <jats:sub>50<\/jats:sub>\n                    ]) of greater than 6. Using HCV pseudotype and replicon systems of multiple HCV genotypes, as well as infectious HCVcc-based assembly and secretion analysis, we determined that different compounds within this group of candidate inhibitors target different steps of viral infection. The compounds identified not only will serve as biological probes to study and further dissect the biology of viral infection but also should facilitate the development of new anti-HCV therapeutic treatments.\n                  <\/jats:p>","DOI":"10.1128\/aac.01413-12","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T02:53:01Z","timestamp":1346813581000},"page":"6109-6120","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infection Using a Cell-Based Assay"],"prefix":"10.1128","volume":"56","author":[{"given":"Xuemei","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Bruno","family":"Sainz","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel A.","family":"Petukhov","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, The University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Uprichard","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Illinois at Chicago, Chicago, Illinois, USA"},{"name":"Department of Microbiology and Immunology, The University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832922"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1440-1746.1999.01875.x","article-title":"Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference","volume":"14","author":"Ahmed A","year":"1999","unstructured":"AhmedA KeeffeEB. 1999. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J. Gastroenterol. Hepatol. 14(Suppl):S12\u2013S18.","journal-title":"J. Gastroenterol. Hepatol."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.053"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9505"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.11.005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021756"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00038-09"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5498.1972"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.5.3181-3190.2003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1021\/jm00038a003","article-title":"Anti-HIV michellamines from Ancistrocladus korupensis","volume":"37","author":"Boyd MR","year":"1994","unstructured":"BoydMR. 1994. Anti-HIV michellamines from Ancistrocladus korupensis. J. Med. Chem. 37:1740\u20131745.","journal-title":"J. Med. Chem."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24803"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1016\/j.bmc.2011.10.009","article-title":"Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors","volume":"19","author":"Carta A","year":"2011","unstructured":"CartaA. 2011. Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. Bioorg. Med. Chem. 19:7070\u20137084.","journal-title":"Bioorg. Med. Chem."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82465-0"},{"key":"e_1_3_3_16_2","volume-title":"Molecular Operating Environment (MOE), 2011.10","author":"Chemical Computing Group Inc","year":"2011","unstructured":"Chemical Computing Group Inc. 2011. Molecular Operating Environment (MOE), 2011.10 Chemical Computing Group Inc., Montreal, Quebec, Canada."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/00498250802613620","article-title":"Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells","volume":"39","author":"Choi S","year":"2009","unstructured":"ChoiS SainzBJr CorcoranP UprichardSL JeongH. 2009. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 39:205\u2013217.","journal-title":"Xenobiotica"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1016\/j.bmc.2007.08.015","article-title":"Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries","volume":"15","author":"Deschamps JD","year":"2007","unstructured":"DeschampsJD. 2007. Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg. Med. Chem. 15:6900\u20136908.","journal-title":"Bioorg. Med. Chem."},{"key":"e_1_3_3_19_2","first-page":"860","article-title":"Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection","volume":"10","author":"Durantel D","year":"2009","unstructured":"DurantelD. 2009. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 10:860\u2013870.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/hep.1840360710","article-title":"Hepatocellular carcinoma and hepatitis C in the United States","volume":"36","author":"El-Serag HB","year":"2002","unstructured":"El-SeragHB. 2002. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36:S74\u201383.","journal-title":"Hepatology"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05654"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/095632020901900604","article-title":"HIV type-1 entry inhibitors with a new mode of action","volume":"19","author":"Fink RC","year":"2009","unstructured":"FinkRC RoschekBJr. AlberteRS. 2009. HIV type-1 entry inhibitors with a new mode of action. Antivir. Chem. Chemother. 19:243\u2013255.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.13.6875-6882.2004"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02053-07"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2010.10.007","article-title":"Oligomeric proanthocyanidins from Rumex acetosa L. inhibit the attachment of herpes simplex virus type-1","volume":"89","author":"Gescher K","year":"2011","unstructured":"GescherK HenselA HafeziW DerksenA KuhnJ. 2011. Oligomeric proanthocyanidins from Rumex acetosa L. inhibit the attachment of herpes simplex virus type-1. Antiviral Res. 89:9\u201318.","journal-title":"Antiviral Res."},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jep.2010.12.038","article-title":"Proanthocyanidin-enriched extract from Myrothamnus flabellifolia Welw. exerts antiviral activity against herpes simplex virus type 1 by inhibition of viral adsorption and penetration","volume":"134","author":"Gescher K","year":"2011","unstructured":"GescherK. 2011. Proanthocyanidin-enriched extract from Myrothamnus flabellifolia Welw. exerts antiviral activity against herpes simplex virus type 1 by inhibition of viral adsorption and penetration. J. Ethnopharmacol. 134:468\u2013474.","journal-title":"J. Ethnopharmacol."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group","volume":"68","author":"Glue P","year":"2000","unstructured":"GlueP. 2000. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68:556\u2013567.","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.13.8400-8409.2005"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5487-5492.2003"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02356-06"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bmc.2011.01.006","article-title":"Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents","volume":"19","author":"Guo RH","year":"2011","unstructured":"GuoRH. 2011. Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents. Bioorg. Med. Chem. 19:1400\u20131408.","journal-title":"Bioorg. Med. Chem."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01548-10"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226136"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0832180100"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700760104"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.neuroscience.2010.03.067","article-title":"Evidence that tricyclic small molecules may possess Toll-like receptor and myeloid differentiation protein 2 activity","volume":"168","author":"Hutchinson MR","year":"2010","unstructured":"HutchinsonMR. 2010. Evidence that tricyclic small molecules may possess Toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168:551\u2013563.","journal-title":"Neuroscience"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.6.2997-3006.2002"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01134-06"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.023"},{"key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.6026\/97320630006100","article-title":"In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme","volume":"6","author":"Kirubakaran P","year":"2011","unstructured":"KirubakaranP. 2011. In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme. Bioinformation 6:100\u2013106.","journal-title":"Bioinformation"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jviromet.2003.10.004","article-title":"Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome","volume":"116","author":"Komurian-Pradel F","year":"2004","unstructured":"Komurian-PradelF. 2004. Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome. J. Virol. Methods 116:103\u2013106.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.10.4614-4624.2001"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1698"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3851\/IMP1597","article-title":"Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication","volume":"20","author":"Li S","year":"2010","unstructured":"LiS. 2010. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication. Antivir. Chem. Chemother. 20:239\u2013248.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114016"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04077"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01888-08"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2341"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.2.866-874.2006"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1021\/jm00116a011","article-title":"Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2","volume":"34","author":"Manfredi KP","year":"1991","unstructured":"ManfrediKP. 1991. Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2. J. Med. Chem. 34:3402\u20133405.","journal-title":"J. Med. Chem."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.484"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22197"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.4067\/S0716-97602002000300016"},{"key":"e_1_3_3_56_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0091270003260336","article-title":"Human liver aldehyde oxidase: inhibition by 239 drugs","volume":"44","author":"Obach RS","year":"2004","unstructured":"ObachRS HuynhP AllenMC BeedhamC. 2004. Human liver aldehyde oxidase: inhibition by 239 drugs. J. Clin. Pharmacol. 44:7\u201319.","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5390.938"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07684"},{"key":"e_1_3_3_59_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1568011033482215","article-title":"Chartreusin, elsamicin A and related anti-cancer antibiotics","volume":"3","author":"Portugal J","year":"2003","unstructured":"PortugalJ. 2003. Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr. Med. Chem. Anticancer Agents 3:411\u2013420.","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15109-4"},{"key":"e_1_3_3_61_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"The Niemann-Pick C1-like 1 cholesterol absorption receptor: a novel hepatitis C virus entry factor and potential therapeutic target","volume":"18","author":"Sainz B","year":"2011","unstructured":"SainzBJr. 2011. The Niemann-Pick C1-like 1 cholesterol absorption receptor: a novel hepatitis C virus entry factor and potential therapeutic target. Nat. Med. 18:281\u2013285.","journal-title":"Nat. Med."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006561"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01059-06"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf529"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1592\/phco.28.2.207","article-title":"Skeletal muscle relaxants","volume":"28","author":"See S","year":"2008","unstructured":"SeeS GinzburgR. 2008. Skeletal muscle relaxants. Pharmacotherapy 28:207\u2013213.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00807.x"},{"key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1074-5521(97)90113-7","article-title":"New insights from spectroscopy into the structure\/function relationships of lipoxygenases","volume":"4","author":"Solomon EI","year":"1997","unstructured":"SolomonEI ZhouJ NeeseF PavelEG. 1997. New insights from spectroscopy into the structure\/function relationships of lipoxygenases. Chem. Biol. 4:795\u2013808.","journal-title":"Chem. Biol."},{"key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2174\/092986711795328382","article-title":"Quinoline as a privileged scaffold in cancer drug discovery","volume":"18","author":"Solomon VR","year":"2011","unstructured":"SolomonVR LeeH. 2011. Quinoline as a privileged scaffold in cancer drug discovery. Curr. Med. Chem. 18:1488\u20131508.","journal-title":"Curr. Med. Chem."},{"key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"21165","DOI":"10.1074\/jbc.M109.004945","article-title":"Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA","volume":"284","author":"Takeshita M","year":"2009","unstructured":"TakeshitaM. 2009. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J. Biol. Chem. 284:21165\u201321176.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_3_70_2","first-page":"125","article-title":"Potential treatment options and future research to increase hepatitis C virus treatment response rate","volume":"2010","author":"Tencate V","year":"2010","unstructured":"TencateV SainzBJr CotlerSJ UprichardSL. 2010. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat. Med. 2010:125\u2013145.","journal-title":"Hepat. Med."},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-010-3134-0"},{"key":"e_1_3_3_72_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1743-422X-3-89","article-title":"Replication of a hepatitis C virus replicon clone in mouse cells","volume":"3","author":"Uprichard SL","year":"2006","unstructured":"UprichardSL ChungJ ChisariFV WakitaT. 2006. Replication of a hepatitis C virus replicon clone in mouse cells. Virol. J. 3:89.","journal-title":"Virol. J."},{"key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-5793(83)80634-6","article-title":"Specific binding of chartreusin, an antitumor antibiotic, to DNA","volume":"153","author":"Uramoto M","year":"1983","unstructured":"UramotoM. 1983. Specific binding of chartreusin, an antitumor antibiotic, to DNA. FEBS Lett. 153:325\u2013328.","journal-title":"FEBS Lett."},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R700024200"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23587"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"e_1_3_3_77_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0463.2010.02586.x","article-title":"Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C","volume":"118","author":"Wang JP","year":"2010","unstructured":"WangJP. 2010. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 118:261\u2013270.","journal-title":"APMIS"},{"key":"e_1_3_3_78_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/abbi.1999.1145","article-title":"Michellamine alkaloids inhibit protein kinase C","volume":"365","author":"White EL","year":"1999","unstructured":"WhiteEL. 1999. Michellamine alkaloids inhibit protein kinase C. Arch. Biochem. Biophys. 365:25\u201330.","journal-title":"Arch. Biochem. Biophys."},{"key":"e_1_3_3_79_2","first-page":"1033","article-title":"Antioxidant activity of michellamine alkaloids","volume":"19","author":"White EL","year":"1999","unstructured":"WhiteEL RossLJ HobbsPD UpenderV DawsonMI. 1999. Antioxidant activity of michellamine alkaloids. Anticancer Res. 19:1033\u20131035.","journal-title":"Anticancer Res."},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21347"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.21.10055-10062.2000"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00495-09"},{"key":"e_1_3_3_83_2","article-title":"Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening","author":"Yu X","year":"2010","unstructured":"YuX UprichardSL. 2010. Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. Curr. Protoc. Microbiol. Chapter 17:Unit 17 5.","journal-title":"Curr. Protoc. Microbiol."},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21994"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503596102"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01413-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01413-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T17:56:36Z","timestamp":1744048596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01413-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1128\/AAC.01413-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01413-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"2012-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}